Oh yes, finally a decent win. Original contract was 2020 Nov for 9.5M and extended with additional 2M in 2022 Dec. This is a big win for ALC and partly vindicates the need to keep employees.

Alcidion signs $23.3M South Tees contract extension until 2033

• Alcidion extends contract with South Tees Hospital NHS Foundation Trust for an additional 8 years for Miya Precision Electronic Patient Record (EPR)
• o Extended contract period is 10 years (to 2033) which includes 2 years remaining on the existing contract
• The minimum contract value is $23.3M (£12.2M) over the new contract period of 10 years
• Further options to include PAS (Silverlink PCS), Emergency Department (ED) and Virtual Care
• modules would add $9.3M (£4.9M) to the minimum contract value
• Options exist to extend for a further 5 years to 2038
• Validates value proposition for Miya Precision Electronic Patient Record (EPR) solution and acts as key reference point for the NHS EPR market 

Just to clarify the sell by Kate was not actually her but the company she owned a stake in @Seasoning. I think some of those websites incorrectly scrap data e.g market index. So her portion was actually $509k

Refer to ann 18/05/2021

Melbourne, Australia – Alcidion Group Limited (ASX: ALC) board has today been advised of a change in

shareholding by several directors, two of whom are substantial shareholders.

MKMS Investment Pty Ltd <MKMS Investment Trust> (MKMS) has sold all the 11.48 million ALC shares

that it held through a broker managed on-market transaction. The sale of shares was undertaken at

$0.34 per share.

MKMS is an entity owned by the five former owners of MKM Health to manage MKM Health’s

investment in Patientrack, both of which were acquired by Alcidion in 2018. MKMS is no longer an

appropriate investment vehicle for the individual parties involved and is therefore being dissolved,

requiring the sale of its interest in Alcidion. The unit holders of MKMS include current and retired

employees of Alcidion, who each continue to hold significant individual shareholdings in Alcidion. Kate

Quirke’s interest in MKMS equated to 1,497,557 million shares, representing approximately 3% of her

shareholding. Ms Quirke retains a cumulative total of 46,561,285 shares.

Simon Chamberlain, a non-executive director, has acquired 295,000 shares at $0.34 as part of the MKMS

managed sale.

Ms Rebecca Wilson and Ms Robyn Morris (spouse of NED Raymond Blight) subscribed for further shares

in the SPP, receiving 15,327 and 93,750 shares, respectively after having their original applications

scaled back in a manner consistent with other SPP applicants. Ms Wilson now holds 1,517,924 shares in

Alcidion.

In accordance with the ASX listing rules, relevant change in Director and Substantial Shareholder

disclosures will be released as appropriate.

Rebecca Wilson, Alcidion Chairsaid, “The sale of MKMS shares to Simon Chamberlain along with several

institutional shareholders further reflects the strong underlying support for Alcidion and assists in

maintaining an orderly market as the MKMS structure is dissolved. All of the underlying unit holders in

MKMS remain significant shareholders in Alcidion, with everyone excited by the growth opportunities

that lie ahead”.

Alcidion Group Ltd (ASX:ALC) has signed a 5-year product licence renewal agreement with Western Sussex Hospitals NHS Trust for Patientrack licensing and support for an additional five years, to 2024.

The total value of the renewal is $970,000.

Alcidion’s group managing director Kate Quirke underlined the importance of the trust’s endorsement of the company’s products in saying, “We are delighted to continue our close partnership with Western Sussex Hospitals NHS Trust - one of our foundation customers in the UK - for the continued use of Patientrack for another five years.

“This demonstrates the longevity of our relationships with customers who have embedded Patientrack into their clinical care.”

Alcidion’s UK general manager Donald Kennedy explained the importance of staying abreast of new healthcare developments in saying, “Our long-standing partnership with Western Sussex NHS Trust has seen several innovations made to Patientrack, and its use has expanded within the trust since it was implemented.

“These include the implementation of world-leading predictive analytics for acute kidney injury, as well as a broad range of clinical assessments and workflow for conditions such as Sepsis.

“This renewal demonstrates the benefits our solutions can bring to patients and health professionals, and the value our solutions can add to wards, hospitals and healthcare systems.”

Kate Quirke has just recently proved that she can sell the Miya solution integrated with Patientrack and Smartpage, and to the UK - Big thumbs up. 

There is strong shareholder alignment with the executive team, notice the directors were buying in heavily back in Dec 2018.

The growth story is in its early days, but it looks like the cross sell opportunity with patient track  should give more wins in the immediate future and the potential of Miya on top of this data suite will enable huge blue sky potential over the next 5 - 10 years.

2018 revenue was 12.7m. 
2019 forecast revenue is 14.8m (not taking into account this new win and any others.)

Assuming they hit 15m in revenue and using a sales multiplier of 5  I would see an immediate valuation of $0.094 in the next 6 months.